{"id":27977,"date":"2017-09-18T03:47:50","date_gmt":"2017-09-17T17:47:50","guid":{"rendered":"https:\/\/haei.org\/?p=27977"},"modified":"2017-09-18T03:48:07","modified_gmt":"2017-09-17T17:48:07","slug":"recommendations-for-prophylaxis-and-treatment-of-hae-attacks","status":"publish","type":"post","link":"https:\/\/haei.org\/recommendations-for-prophylaxis-and-treatment-of-hae-attacks\/","title":{"rendered":"Recommendations for Prophylaxis and Treatment of HAE Attacks"},"content":{"rendered":"<p>The Food and Drug Administration (FDA) has recently received reports from patients, physicians, and specialty pharmacies that they have been unable to obtain C1-Esterase Inhibitor (Human) Cinryze. Healthcare providers and patients may wish to consider alternate treatment options, including:<\/p>\n<p><strong>For Prophylaxis:<\/strong> Haegarda was recently licensed for prophylaxis of HAE attacks. Haegarda is administered subcutaneously, twice a week. Information about Haegarda, including the prescribing information, is posted on FDA\u2019s web site.<\/p>\n<p><strong>For Treatment:<\/strong> It is important for patients, even those on prophylaxis, to make sure they have rapid access to treat any acute HAE attacks. Four products are licensed for treatment of HAE attacks:<\/p>\n<ul>\n<li>Berinert (CSL Behring)<\/li>\n<li>Ruconest (Pharming)<\/li>\n<li>Firazyr (Shire)<\/li>\n<li>Kalbitor (Dyax Corporation)<\/li>\n<\/ul>\n<p>FDA recommends that patients with HAE work closely with their health care professionals. Your doctor is in the best position to assess your medical situation and determine your best course of treatment.<\/p>\n<p>If you have additional questions, please feel free to contact FDA\u2019s Center for Biologics Evaluation and Research by phone at (800) 835-4709, (240) 402-8010, or by email at ocod@fda.hhs.gov.<br \/>\n<em>(Source: FDA)<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Food and Drug Administration (FDA) has recently received reports from patients, physicians, and specialty pharmacies that they have been unable to obtain C1-Esterase Inhibitor (Human) Cinryze. Healthcare providers and patients may wish to consider alternate treatment options, including: For Prophylaxis: Haegarda was recently licensed for prophylaxis of HAE attacks. Haegarda is administered subcutaneously, twice [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Recommendations for Prophylaxis and Treatment of HAE Attacks - HAE International (HAEi)<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/haei.org\/recommendations-for-prophylaxis-and-treatment-of-hae-attacks\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Recommendations for Prophylaxis and Treatment of HAE Attacks - HAE International (HAEi)\" \/>\n<meta property=\"og:description\" content=\"The Food and Drug Administration (FDA) has recently received reports from patients, physicians, and specialty pharmacies that they have been unable to obtain C1-Esterase Inhibitor (Human) Cinryze. Healthcare providers and patients may wish to consider alternate treatment options, including: For Prophylaxis: Haegarda was recently licensed for prophylaxis of HAE attacks. Haegarda is administered subcutaneously, twice [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/haei.org\/recommendations-for-prophylaxis-and-treatment-of-hae-attacks\/\" \/>\n<meta property=\"og:site_name\" content=\"HAE International (HAEi)\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/haeinternational\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-09-17T17:47:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-09-17T17:48:07+00:00\" \/>\n<meta name=\"author\" content=\"Henrik Balle Boysen\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@haeday\" \/>\n<meta name=\"twitter:site\" content=\"@haeday\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Henrik Balle Boysen\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/haei.org\/recommendations-for-prophylaxis-and-treatment-of-hae-attacks\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/haei.org\/recommendations-for-prophylaxis-and-treatment-of-hae-attacks\/\"},\"author\":{\"name\":\"Henrik Balle Boysen\",\"@id\":\"https:\/\/haei.org\/#\/schema\/person\/025e1a441ffed388e4b45759960bbf35\"},\"headline\":\"Recommendations for Prophylaxis and Treatment of HAE Attacks\",\"datePublished\":\"2017-09-17T17:47:50+00:00\",\"dateModified\":\"2017-09-17T17:48:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/haei.org\/recommendations-for-prophylaxis-and-treatment-of-hae-attacks\/\"},\"wordCount\":188,\"publisher\":{\"@id\":\"https:\/\/haei.org\/#organization\"},\"articleSection\":[\"HAEi News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/haei.org\/recommendations-for-prophylaxis-and-treatment-of-hae-attacks\/\",\"url\":\"https:\/\/haei.org\/recommendations-for-prophylaxis-and-treatment-of-hae-attacks\/\",\"name\":\"Recommendations for Prophylaxis and Treatment of HAE Attacks - HAE International (HAEi)\",\"isPartOf\":{\"@id\":\"https:\/\/haei.org\/#website\"},\"datePublished\":\"2017-09-17T17:47:50+00:00\",\"dateModified\":\"2017-09-17T17:48:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/haei.org\/recommendations-for-prophylaxis-and-treatment-of-hae-attacks\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/haei.org\/recommendations-for-prophylaxis-and-treatment-of-hae-attacks\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/haei.org\/recommendations-for-prophylaxis-and-treatment-of-hae-attacks\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/haei.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Recommendations for Prophylaxis and Treatment of HAE Attacks\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/haei.org\/#website\",\"url\":\"https:\/\/haei.org\/\",\"name\":\"HAE International (HAEi)\",\"description\":\"HAE International (HAEi) is the global umbrella organization for the world\u2019s Hereditary Angioedema (HAE) patient groups.\",\"publisher\":{\"@id\":\"https:\/\/haei.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/haei.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/haei.org\/#organization\",\"name\":\"HAE International\",\"url\":\"https:\/\/haei.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/haei.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/haei.org\/wp-content\/uploads\/2018\/10\/logo.png\",\"contentUrl\":\"https:\/\/haei.org\/wp-content\/uploads\/2018\/10\/logo.png\",\"width\":162,\"height\":82,\"caption\":\"HAE International\"},\"image\":{\"@id\":\"https:\/\/haei.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/haeinternational\/\",\"https:\/\/x.com\/haeday\",\"https:\/\/www.linkedin.com\/company\/haei---international-patient-organization-for-c1-inhibitor-deficiencies\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/haei.org\/#\/schema\/person\/025e1a441ffed388e4b45759960bbf35\",\"name\":\"Henrik Balle Boysen\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/haei.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/4823f37a6c07106279cad7dc0d24e815?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/4823f37a6c07106279cad7dc0d24e815?s=96&d=mm&r=g\",\"caption\":\"Henrik Balle Boysen\"},\"url\":\"https:\/\/haei.org\/author\/boysen\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Recommendations for Prophylaxis and Treatment of HAE Attacks - HAE International (HAEi)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/haei.org\/recommendations-for-prophylaxis-and-treatment-of-hae-attacks\/","og_locale":"en_US","og_type":"article","og_title":"Recommendations for Prophylaxis and Treatment of HAE Attacks - HAE International (HAEi)","og_description":"The Food and Drug Administration (FDA) has recently received reports from patients, physicians, and specialty pharmacies that they have been unable to obtain C1-Esterase Inhibitor (Human) Cinryze. Healthcare providers and patients may wish to consider alternate treatment options, including: For Prophylaxis: Haegarda was recently licensed for prophylaxis of HAE attacks. Haegarda is administered subcutaneously, twice [&hellip;]","og_url":"https:\/\/haei.org\/recommendations-for-prophylaxis-and-treatment-of-hae-attacks\/","og_site_name":"HAE International (HAEi)","article_publisher":"https:\/\/www.facebook.com\/haeinternational\/","article_published_time":"2017-09-17T17:47:50+00:00","article_modified_time":"2017-09-17T17:48:07+00:00","author":"Henrik Balle Boysen","twitter_card":"summary_large_image","twitter_creator":"@haeday","twitter_site":"@haeday","twitter_misc":{"Written by":"Henrik Balle Boysen","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/haei.org\/recommendations-for-prophylaxis-and-treatment-of-hae-attacks\/#article","isPartOf":{"@id":"https:\/\/haei.org\/recommendations-for-prophylaxis-and-treatment-of-hae-attacks\/"},"author":{"name":"Henrik Balle Boysen","@id":"https:\/\/haei.org\/#\/schema\/person\/025e1a441ffed388e4b45759960bbf35"},"headline":"Recommendations for Prophylaxis and Treatment of HAE Attacks","datePublished":"2017-09-17T17:47:50+00:00","dateModified":"2017-09-17T17:48:07+00:00","mainEntityOfPage":{"@id":"https:\/\/haei.org\/recommendations-for-prophylaxis-and-treatment-of-hae-attacks\/"},"wordCount":188,"publisher":{"@id":"https:\/\/haei.org\/#organization"},"articleSection":["HAEi News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/haei.org\/recommendations-for-prophylaxis-and-treatment-of-hae-attacks\/","url":"https:\/\/haei.org\/recommendations-for-prophylaxis-and-treatment-of-hae-attacks\/","name":"Recommendations for Prophylaxis and Treatment of HAE Attacks - HAE International (HAEi)","isPartOf":{"@id":"https:\/\/haei.org\/#website"},"datePublished":"2017-09-17T17:47:50+00:00","dateModified":"2017-09-17T17:48:07+00:00","breadcrumb":{"@id":"https:\/\/haei.org\/recommendations-for-prophylaxis-and-treatment-of-hae-attacks\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/haei.org\/recommendations-for-prophylaxis-and-treatment-of-hae-attacks\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/haei.org\/recommendations-for-prophylaxis-and-treatment-of-hae-attacks\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/haei.org\/"},{"@type":"ListItem","position":2,"name":"Recommendations for Prophylaxis and Treatment of HAE Attacks"}]},{"@type":"WebSite","@id":"https:\/\/haei.org\/#website","url":"https:\/\/haei.org\/","name":"HAE International (HAEi)","description":"HAE International (HAEi) is the global umbrella organization for the world\u2019s Hereditary Angioedema (HAE) patient groups.","publisher":{"@id":"https:\/\/haei.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/haei.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/haei.org\/#organization","name":"HAE International","url":"https:\/\/haei.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/haei.org\/#\/schema\/logo\/image\/","url":"https:\/\/haei.org\/wp-content\/uploads\/2018\/10\/logo.png","contentUrl":"https:\/\/haei.org\/wp-content\/uploads\/2018\/10\/logo.png","width":162,"height":82,"caption":"HAE International"},"image":{"@id":"https:\/\/haei.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/haeinternational\/","https:\/\/x.com\/haeday","https:\/\/www.linkedin.com\/company\/haei---international-patient-organization-for-c1-inhibitor-deficiencies\/"]},{"@type":"Person","@id":"https:\/\/haei.org\/#\/schema\/person\/025e1a441ffed388e4b45759960bbf35","name":"Henrik Balle Boysen","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/haei.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/4823f37a6c07106279cad7dc0d24e815?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4823f37a6c07106279cad7dc0d24e815?s=96&d=mm&r=g","caption":"Henrik Balle Boysen"},"url":"https:\/\/haei.org\/author\/boysen\/"}]}},"distributor_meta":false,"distributor_terms":false,"distributor_media":false,"distributor_original_site_name":"HAE International (HAEi)","distributor_original_site_url":"https:\/\/haei.org","push-errors":false,"_links":{"self":[{"href":"https:\/\/haei.org\/wp-json\/wp\/v2\/posts\/27977"}],"collection":[{"href":"https:\/\/haei.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haei.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haei.org\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/haei.org\/wp-json\/wp\/v2\/comments?post=27977"}],"version-history":[{"count":0,"href":"https:\/\/haei.org\/wp-json\/wp\/v2\/posts\/27977\/revisions"}],"wp:attachment":[{"href":"https:\/\/haei.org\/wp-json\/wp\/v2\/media?parent=27977"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haei.org\/wp-json\/wp\/v2\/categories?post=27977"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haei.org\/wp-json\/wp\/v2\/tags?post=27977"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}